MarginsXMarginsX
Home › Markets › Health Care › ALVO

Alvotech (ALVO)

ALVO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.41
+5.13% on the day
Market cap
$1.7B
Small cap
Revenue · 2025
$586.3M
+19.7% on 2024
Net income · 2025
$27.9M
4.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/0001898416-26-000004-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerALVO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryLuxembourg
IPO yearNot reported by the screener
SEC CIK0001898416
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inLuxembourg

Financials · 2025

LineValue
Revenue$586.3M
Net income$27.9M
Operating income$78.2M
Net margin4.8%
Operating margin13.3%
Revenue growth+19.7%
Cash$172.4M
Total assets$1.5B
P/E (computed)61.6×
P/S (computed)2.9×

Warning signs

Cash runway
41.2 months
$172.4M cash at December 31, 2025
Share count, 1 year
+3.4%
2024-12-31 to 2025-12-31 · +25.5% over 3 years
Going-concern doubt
No
20-F filed March 31, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-31
Cash and burn$172.4M cash; operating cash flow -$12.5M a quarter.Report 2025-12-31
Shares outstanding312,021,375 (2025-12-31); 301,805,677 a year earlier; 248,649,506 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-06-16
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte ehf., Kopavogur, IcelandPCAOB Form AP 2026-04-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$586.3M$27.9M-$50.2M$172.4M$1.3B$586.3M20-F 2026-03-31
FY 2024
2024-12-31
$489.7M-$231.9M-$236.8M$51.4M$1.1B$489.7M20-F 2026-03-31
FY 2023
2023-12-31
$91.4M-$551.7M-$312.2M$11.2M$960.2M$91.4M20-F 2026-03-31
FY 2022
2022-12-31
$83.0M-$513.6M-$312.4M$66.4M$764.6M$83.0M20-F 2025-03-27
FY 2021
2021-12-31
$36.8M-$101.5M-$228.2M$17.6M$400.9M$36.8M20-F 2024-03-20
FY 2020
2020-12-31
$66.6M-$170.0M-$74.3M$31.7M$567.9M$66.6M20-F 2023-03-01

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-16
Latest annual report20-F2026-03-31
Latest quarterly / interim
FORM 6-K
6-K2026-11-12

Source: SEC EDGAR submissions feed, 304 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.8%
1 month-22.1%
3 months+2.4%
Year to date-18.3%
1 year-24.1%
From 52-week high-31.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
ALVOWAlvotech Warrant$0.2753

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
WWBWindward Bio Group AG Common Shares$30.04+5.40%$1.7B
VIRVir Biotechnology Inc.$9.58-3.82%$1.6B
RXRXRecursion Pharmaceuticals Inc.$2.90-8.79%$1.8B
COAGHemab Therapeutics Holdings Inc.$39.05-4.42%$1.8B
MESOMesoblast Limited$12.45-6.18%$1.6B
MAZEMaze Therapeutics Inc.$33.90-1.25%$1.9B
BCRXBioCryst Pharmaceuticals Inc.$7.45-2.10%$1.9B
IMCRImmunocore Holdings plc$28.88-3.54%$1.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier